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Background: Many drugs are available for control of hypertension and its sequels in Nigeria but some are not
affordable for majority of the populace. This serious pharmacoeconomic question has to be answered by the
nation’s health economists. The objective of this study was to evaluate the cost-effectiveness of drugs from 4
classes of antihypertensive medications commonly used in Nigeria in management of hypertension without
compelling indication to use a particular antihypertensive drug.
Methods: The study employed decision analytic modeling. Interventions were obtained from a meta-analysis. The
Markov process model calculated clinical outcomes and costs during a life cycle of 30 years of 1000 hypertensive
patients stratified by 3 cardiovascular risk groups, under the alternative intervention scenarios. Quality adjusted life
year (QALY) was used to quantify clinical outcome. The average cost of treatment for the 1000 patient was tracked
over the Markov cycle model of the alternative interventions and results were presented in 2010 US Dollars.
Probabilistic cost-effectiveness analysis was performed using Monte Carlo simulation, and results presented as
cost-effectiveness acceptability frontiers. Expected value of perfect information (EVPI) and expected value of
parameter perfect information (EVPPI) analyses were also conducted for the hypothetical population.
Results: Thiazide diuretic was the most cost-effective option across the 3 cardiovascular risk groups. Calcium channel
blocker was the second best for Moderate risk and high risk with a willingness to pay of at least 2000$/QALY. The
result was robust since it was insensitive to the parameters alteration.
Conclusions: The result of this study showed that thiazide diuretic followed by calcium channel blocker could be a
feasible strategy in order to ensure that patients in Nigeria with hypertension are better controlled.Introduction
Hypertension is a disturbance in hemodynamic function
in which there is persistent abnormal elevation of sys-
temic blood pressure, whether it is diastolic or systolic
above the level of normal pressure of 140/90 mmHg [1].
It is regarded as a silent killer. Hypertension has a rela-
tionship with other cardiovascular diseases. Increasing
blood pressure increases the risk of developing other
cardiovascular diseases like stroke or coronary heart dis-
ease (CHD) [2].
There is growing evidence that prevalence of hyperten-
sion is on the increase in most sub-Saharan African coun-
tries including Nigeria [3]. A Meta analysis of prevalence
rate of hypertension in Nigerian populations ranged from* Correspondence: obinna.ekwunife@unn.edu.ng
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reproduction in any medium, provided the ora minimum of 12.4% to a maximum of 34.8% with a com-
bined prevalence of 22% [4]. With increasing prevalence
and poorer control of hypertension, many people will be
predisposed to cardiovascular events such as CHD and
stroke. Such cardiovascular disease events will place a
huge economic burden on the Nigerian economy since
they are expensive to manage. Many drugs are now avail-
able for control of hypertension and its sequels but some
are not affordable for majority of people in Nigeria. This
serious pharmacoeconomic question has to be answered
by the nation’s health economists.
Recent hypertension guidelines stress the usefulness of 4
classes of antihypertensive drugs i.e. thiazide diuretic, beta-
blockers (BBs), angiotensin converting enzyme inhibitors
(ACEIs), and calcium channel blockers (CCBs) which have
been shown to be very effective compared to the others
[5]. These drugs happened to be the predominant antihy-
pertensive agents used in Nigeria. Therefore, the objectiveal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from these 4 classes of antihypertensive medications for
use in management of hypertension in Nigerians without
compelling indication to use a particular antihypertensive
drug.
Methods
Effect sizes of hypertensive medication
The hypertensive medication selected for evaluation was
based on a published systematic review whose aim was
to evaluate the medication which should be first-line
drug of choice for hypertension [5]. The study included
randomized trials of at least one year duration, compar-
ing one of 4 major classes of antihypertensive drugs
(Table 1). More than 70% of the population of interest
had BP > 140/90 mmHg at baseline [5]. The medications
were classified as thiazide diuretic; BB; ACEI; and CCB.
For the purpose of our study, hydrochlorothiazide, pro-
pranolol, lisinopril and nifedipine were the represen-
tative drugs for thiazide diuretic, BB, ACEI and CCB
respectively as these drugs are commonly used in
Nigeria [6].
Markov model
The model life cycle used to calculate the cost, effect
and cost-effectiveness of the alternative interventions to
manage hypertension is shown in Figure 1. This cohort
simulation (Markov process model) calculated clinical
outcomes and costs during a life cycle of 30 years for
1000 people under the alternative intervention scenarios.
The starting age of hypertensive patients in the model
was 40 years. It was assumed that these hypertensive
patients will start as asymptomatic and with each year
that passes (Markov state), people may remain asymp-
tomatic; they may experience any of the two major car-
diovascular events which are stroke and coronary heart
disease (CHD); they may remain in stroke or CHD (non-
fatal); they may die from cardiovascular disease or may
die from other causes not related to cardiovascular dis-
ease. The probabilities of these outcomes depended on
the risk profile (as shown in Tables 2 and 3). Case fatal-
ity rates for stroke and CHD were 27% and 51% respect-
ively [7].
Quality Adjusted Life Years (QALYs) was used to
quantify clinical outcome. The health related quality of




Angiotensin converting enzyme inhibitor (ACEI)
Calcium channel blocker (CCB)stroke, and CHD) were obtained from the data of a
health utility state assessment carried out in Nigeria [8].
To obtain the QALYs which represent the clinical out-
come, the weights were multiplied by the number of life
years spent in the different states, and then averaged
over a life time of 30 years with a utility discount of 3%.
This was done for the different interventions. The aver-
age cost of treatment for the 1000 patients was tracked
over the Markov cycle model for all the interventions in-
cluding null scenario. The average QALYs and costs
were calculated by summing up the QALYs and costs re-
spectively over a period of 30 years and then dividing by
the population (1000 patients). Financial values were
presented in 2010 US dollars. Discount of 3% at baseline
were use for both cost and effects.
A Null scenario was included in this model. The null
scenario refers to the case where the patients at asymp-
tomatic stage (1000 patients) are not receiving any of
the antihypertensive medications under evaluation. The
null scenario however, included the cost of management
and the cost of hospitalization for the hypertension-
related complications (stroke and CHD). The reason for
including the null scenario in this model is to calculate
the extra cost that will be incurred if the patients began
to treat their hypertension at asymptomatic stage with
any of the medications under study and also to evaluate
if the patients in their asymptomatic stage who began
treatment with any of the antihypertensive drugs will
have a higher or lower quality of life years (QALYs)
when compared to the case where the patients at their
asymptomatic stage received no treatment (null scenario)
until they had stroke or CHD. The extra cost (incremental
cost) and the difference in QALY was used to evaluate
which of the antihypertensive agents or null scenario is
the most cost-effective.
Calculating risk of cardiovascular event
A web-based recalibrated Framingham risk score designed
for estimating 10-year risk of stroke and CHD in seven
British black and minority group was used to estimate the
risk of stroke and CHD of the different age group [9].
Since the recalibration of the risk scores was done with
Africans in Britain, its use in this model will give a bet-
ter risk prediction as there was no published study that
predicted cardiovascular events over time in Africans
that could be used for this model. The World Healthypertension
Drug Dosage (daily)
Hydrochlorothiazide Tab. 25 mg
Propranolol Tab. 40 mg qid
Lisinopril Tab. 10 mg












Figure 1 The life cycle model used to calculate the costs, effects and cost-effectiveness of the alternative interventions to manage
hypertension.
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diovascular risk stratification (low risk, medium risk and
high risk) was used to stratify the patients [10]. Index
patients used for low risk patients were such that their
highest 10 years risk of stroke or CHD were less than 15%
at the age of 50. Index patients used to depict medium risk
had 10 years stroke or CHD risk of 15% to 20% at the age
of 50 while high risk patients had 10 years stroke or CHD
risk of greater than 20% at the age of 50. Average values of
total cholesterol and high density lipoprotein (HDL) in
Nigerians were used for stroke and CHD risk calculation.
The values were obtained from a prospective population
survey conducted in Port Harcourt, a city located in
southern part of Nigeria [11]. The 10 years risk of stroke
or CHD was converted to one year risk (annual transition
probabilities) [12].
Determination of cost
Cost was estimated from the providers’ perspective (third
party payer). Providers’ perspective requires mainly the
direct cost to be measured [13]. In this study, the direct
cost includes cost of medications; cost of physician visit;
cost of in-patient stay; cost of physiotherapy; and cost ofTable 2 Index patients, with annual risks of CHD and stroke
Age Low risk Me
High BP Controlled BP High BP
CHD Stroke CHD Stroke CHD Stroke
40 0.0010 0.0041 0.0010 0.0030 0.0041 0.0105
45 0.0020 0.0062 0.0010 0.0041 0.0051 0.0150
50 0.0030 0.0094 0.0020 0.0051 0.0072 0.0221
55 0.0041 0.0138 0.0030 0.0083 0.0105 0.0310
60 0.0051 0.0196 0.0041 0.0116 0.0150 0.0452
65 0.0072 0.0284 0.0062 0.0161 0.0209 0.0651
70 0.0105 0.0407 0.0083 0.0233 0.0297 0.0922
Total Cholesterol – 4.76 ± 1.06.
HDL Cholesterol – 0.90 ± 0.25.
Smoker – Low Risk = No; Medium Risk = No; High Risk = Yes.laboratory tests. Cost of medications were gotten from the
Nigerian National Health Insurance Scheme (NHIS) drug
price list, published in 2005 [14], except for Mannitol
(20% IVF) whose cost was gotten from the 2010 Inter-
national Drug Price Indicator Guide of the WHO [12].
Cost of in-patient stay, physician visit (1st and review),
computed tomography scan, echocardiography, electro-
cardiography and urinalysis were also obtained from the
NHIS drug price list [14]. Cost gotten from the 2005
NHIS drug price list were adjusted to reflect the future
(2010) value using a real interest rate of 3% (range of 0% -
5%). For cost obtained from the International Drug Price
Index (Mannitol), the median price was used and multi-
plied by the Power Purchasing Parity Exchange Rate (PPP)
to obtain the value in Naira which was then divided by the
yearly exchange rate to obtain the US dollar equivalent
[15,16]. The cost of magnetic resonance imaging (MRI),
full blood count (FBC) and serum electrolyte and urea
analysis (SEU) were gotten from the price list of University
of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla.
For patients at the asymptomatic hypertension stage,
their direct costs include cost of any of the antihyperten-
sive medication under study and cost of physician visit.dium risk High risk
Controlled BP High BP Controlled BP
CHD Stroke CHD Stroke CHD Stroke
0.0030 0.0051 0.0072 0.0221 0.0041 0.0094
0.0041 0.0072 0.0094 0.0323 0.0062 0.0127
0.0051 0.0105 0.0138 0.0467 0.0083 0.0185
0.0072 0.0150 0.0185 0.0670 0.0116 0.0271
0.0105 0.0221 0.0271 0.0946 0.0161 0.0393
0.0150 0.0323 0.0378 0.1330 0.0233 0.0563
0.0209 0.0452 0.0530 0.1846 0.0323 0.0809
Table 3 Nigerian Life Table – Yearly age specific mortality
rate (29)











90 and above 90 0.32027
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365 days in a year while physician visit was made to be
monthly (i.e. 12 times per annum). For Stroke patients
hospitalized, the direct costs used in the model were cost
of medical therapy (mannitol and furosemide), in-patient
stay, laboratory tests and physiotherapy. For CHD patients
hospitalized, the direct costs used in the model were cost
of medical therapy (nifedipine and nitroglycerin), in-
patient stay and laboratory tests. The costs were calcu-
lated as annual costs under the following headings: cost
for use of thiazide; cost for use of lisinopril; cost for use of
nifedipine; cost for use of propranolol; cost to hospitalize
stroke patients; cost to manage stroke patients; cost to
hospitalize CHD patients; and cost to manage CHD
patients. A triangular distribution was used to calculate
the annual costs under the headings listed above.
The cost of providing health care to hypertensive
patients (asymptomatic) and those with hypertension-
related complications in the null was estimated first
before determining the incremental cost that will be in-
curred if the patients from their asymptomatic stage to
hypertension-related complications (stroke and CHD)
had consume any of the four antihypertensive drugs
(propranolol, HCTZ, Nifedipine and Lisinopril) under
evaluation. The summary of the interventions cost are
shown in Table 4.Handling uncertainty
Distributions appropriate for each variable were employed
in order to capture the varying degree of inherent un-
certainty in the variables used in the analysis (Table 5).
Probabilistic sensitivity analysis was used to assess simul-
taneous uncertainty in many variables. This approach is
well suited to express overall parameter uncertainty [9]. A
total of 1000 iterations of Monte Carlo simulations were
conducted and for each iteration, a value was drawnrandomly from each distribution and net health benefits
calculated [9].
Net monetary benefit calculation
The application of net monetary benefit (NMB) ap-
proach has its importance in overcoming the problems
associated with incremental cost-effectiveness ratios
(ICERs) [17]. This was obtained by applying the formula
below:
NMB ¼ ΔQALYi  ΔCosti=λð Þ ð1Þ
Where NMB = Net monetary benefit
QALY = Quality adjusted life years
λ = Threshold ratio
In the net monetary benefit approach, a strategy or
intervention is considered cost-effective if it produces a
positive net benefit [12]. On the other hand, a negative
net benefit means that the intervention is considered
not to be cost-effective and as such, will not be con-
sidered. For each iteration, the intervention with the
highest NMB is designated the value ‘1’ while other
intervention for that iteration will the value ‘0’. After
1000 iterations, the values (1 or 0) for each intervention
are summed and averaged to obtain their probabilities
of cost-effectiveness.
The cost-effectiveness threshold (CET) used in this
evaluation was $15,000 which is the maximum amount
the providers’ will be willing to pay, to achieve the best
therapeutic outcome for their clients. The CET used was
just an arbitrary figure within range that will aid to ob-
tain the final result.
Cost-effectiveness acceptability frontier
Cost-effectiveness acceptability frontiers were used to
present the result of cost-effectiveness for the 3 different
cardiovascular risk scenarios. The cost-effectiveness ac-
ceptability frontiers illustrate the probability of any inter-
vention being optimal compared to all other competing
alternatives. Cost-effectiveness frontier also illustrates
the crossover when one intervention is substituted by
the other as the one with the highest probability of being
optimal and therefore provides useful information for
policy makers [18]. The major difference between the
frontier and curve is that the frontier takes into consid-
eration the null scenarios in addition to the alternative
interventions while the acceptability curve considers all
the interventions except the null scenario. A total of 58
iterations of simulations were conducted for different
willingness-to-pay threshold ratio. For each iteration, the
probability that the cost-effectiveness of any intervention
Table 4 Data Inputs and distribution in Markov model
Variable Mean/Mode Distribution Source
Probabilities
Probabilities of non-symptomatic to stroke or CHD See Table 2 Gamma 6
Probability from stroke to Death 0.27 Beta (α 0.27, β 0.73) 29
Probability from CHD to Death 0.51 Beta (α 0.49, β 0.51) 29
Relative Risk
Relative Risk of Thiazide to Stroke 0.63 Normal (α 0.63, se 0.056) 4
Relative Risk of Thiazide to CHD 0.84 Normal (α 0.84, se 0.060) 4
Relative Risk of Thiazide to Death 0.89 Normal (α 0.89, se 0.037) 4
Relative Risk of Propranolol to Stroke 0.83 Normal (α 0.83, se 0.076) 4
Relative Risk of Propranolol to CHD 0.90 Normal (α 0.90, se 0.071) 4
Relative Risk of Propranolol to Death 0.96 Normal (α 0.96, se 0.056) 4
Relative Risk of Lisinopril to Stroke 0.65 Normal (α 0.65, se 0.116) 4
Relative Risk of Lisinopril to CHD 0.81 Normal (α 0.81, se 0.075) 4
Relative Risk of Lisinopril to Death 0.83 Normal (α 0.83, se 0.071) 4
Relative Risk of Nifedipine to Stroke 0.58 Normal (α 0.58, se 0.183) 4
Relative Risk of Nifedipine to CHD 0.77 Normal (α 0.77, se 0.174) 4
Relative Risk of Nifedipine to Death 0.86 Normal (α 0.86, se 0.120) 4
Resources (Annual cost/patient in US Dollars)
Thiazide 89.69 Triangular (min 71.75, max 107.63) 11
Propranolol 103.36 Triangular (min 82.69, max 124.03) 11
Lisinopril 404.08 Triangular (min 323.26, max 484.89) 11
Nifedipine 294.72 Triangular (min 235.78, max 353.67) 11
Hospitalization cost for Stroke 873.62 Triangular (min 698.89, max 1048.34) 11,12,UNTH
Hospitalization cost for CHD 311.73 Triangular (min 249.39, max 374.08) 11, UNTH
Management of Stroke and CHD Patients 417.74 Triangular (min 334.20, max 501.29) 11
Health Utilities
Hypertensive patients 0.57 Beta (α 206.1, β 155.1) Unpublished
Stroke Patients 0.04 Beta (α 1.0, β 23.3) Unpublished
CHD 0.13 Beta (α 4.9, β 32.9) Unpublished
Discount Rate
Cost and Utility 3% Triangular (min 0%, max 5%) 30
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for all the alternative interventions from the NMB [12].Assessment of population values of perfect information
(EVPI)
Population Expected Value of Perfect Information
(EVPI) was carried out for the three cardiovascular risk
scenarios to determine the opportunity cost surrounding
the conclusion of the analysis [12]. The population EVPI
was conducted for 1000 patients over the life cycle of 30
years period. Simulation for 58 iterations were con-
ducted for different willingness-to-pay threshold ratio
and for each iteration, a value of perfect information foreach willingness-to-pay threshold was calculated with
the use of the effective population [12].
Across the four anti-HTs under evaluation including
null scenario, the highest NMB for each iteration was
selected. The highest NMBs for all the iterations were
averaged. The difference between this average value
obtained and the highest averaged NMB across the dif-
ferent interventions was noted. In calculating the Dis-
count Population for the 1000 patients over a period of
30 years, a discount rate of 3% (range of 0% - 5%) was
used. The sum of the discount population over 30 years
is the Effective Population. The Population EVPI was
obtained by multiplying the Effective Population with
the difference in NMB noted.
Table 5 Expected Value of Perfect Information (1000
Patients, 30 years)
Intervention* Willingness to pay ($/QALY) Population EVPI ($)
Low Risk
Null Scenario - -
Thiazide diuretic 2,700 2,066,053
ACEI 15,000 18,246,980
Medium Risk
Null Scenario - -
Thiazide diuretic 1,300 1,235,304
CCB 15,000 38,307,837
High Risk
Null Scenario - -
Thiazide 1,400 894,629
CCB 12,500 22,299,390
*Intervention are presented in decreasing order of cost-effectiveness.
ACEI – Angiotensin converting enzyme inhibitor; CCB – Calcium channel
blocker.
Figure 2 Cost-effectiveness acceptability frontier for the
alternative interventions in the low cardiovascular risk scenario.
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(EVPPI)
The expected value of perfect information for para-
meters (EVPPI) was obtained by multiplying the effective
population with the difference between the net-benefit
with perfect information and the expected value with
current information about the parameter(s) [12]. The
EVPPI was also conducted for 1000 patients. This as-
sessment was started by checking the threshold ratio
and set to the maximum in order to give a high EVPI.
The parameters assessed were relative risk (RR), utility
and cost. A total of 100 iterations of Monte Carlo simu-
lation were conducted and for each parameter, the net-
benefit was obtained 10 times by repeating the process
so as to calculate the mean net-value. The perfect infor-
mation pay-off, given certainty over each parameter was
determined in order to obtain the EVPPI.
Data analyses
All analyses (i.e. Markov chain analysis, Monte Carlo
simulation, and assessment of value of perfect informa-
tion) were carried out using Microsoft Excel (Microsoft
Corporation, 2007).
Results
For the three cardiovascular risk groups, the yearly cost
in the null scenario was the least. The null scenario also
had the least QALYs in the three groups. In all the car-
diovascular risk states (CVRSs), ACEI has the highest
annual cost if used followed by calcium-channel blocker.
ACEI has a low QALY in the medium and high risk state
but the highest QALY in the low CVRS. Thiazide diur-
etic has a very low annual cost in the three states, the
highest QALYs in the medium and high risk state butnot in the low CVRS. In the low CVRS, at any threshold
ratio ($0 - $15,000), ACEI has the highest NMB followed
by thiazide but in the medium and high CVRSs, thiazide
has the highest NMB followed by calcium-channel
blocker at any threshold ratio. For instance, in the
medium risk, at threshold ratio of $15,000, the NMB of
the various interventions are as follows: null scenario
($89799); thiazide ($101927); beta-blocker ($94094);
ACEI ($98619); Calcium-channel blocker ($101780).
The null scenario in the three cardiovascular risk
groups has a 0 (zero) probability of being cost effective.
In the low CVRS, ACEI has the highest probability of
being cost effective (about 0.526) followed by thiazide di-
uretic (about 0.278). In the medium and high CVRSs,
calcium-channel blocker has the highest probability of
being cost effective (about 0.47 and 0.53) followed by
thiazide diuretic (about 0.45 and 0.41) respectively.
The application of cost-effectiveness acceptability fron-
tier is to help determine which antihypertensive agent has
the highest probability of being cost-effective when com-
pared with other alternative drugs. For low cardiovascular
risk state (Figure 2), at no willingness-to-pay, null scenario
was the most cost-effective (if the provider is not willing
to invest any money to achieve a higher health outcome).
When the provider is ready to pay any amount above
$2,600 but not more than $15,000 for additional QALY,
thiazide diuretic emerged as the best intervention. If the
provider is willing to pay greater than $15,000 for add-
itional QALY, ACEI emerged as the best intervention. In
Figure 3, cost-effectiveness frontier for patients in medium
cardiovascular state is shown. At no willingness-to-pay,
null scenario was the most cost-effective. When the pro-
vider is ready to pay any amount above $1,300 but not
more than $15,000 for additional QALY, thiazide emerged
Figure 3 Cost-effectiveness acceptability frontier for the
alternative interventions in the moderate cardiovascular risk
scenario.
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greater than $15,000 for additional QALY, calcium-
channel blocker emerged as the best intervention. Similar
result was also obtained for patient in high cardiovascular
risk state (Figure 4). At no willingness-to-pay, null sce-
nario was the most cost-effective. When the provider is
ready to pay any amount above $1,300 but not more than
$15,000 for additional QALY, thiazide emerged as the best
intervention. If the provider is willing to pay greater than
$12,500 for additional QALY, calcium-channel blocker
emerged as the best intervention.Figure 4 Cost-effectiveness acceptability frontier for the
alternative interventions in the high cardiovascular risk
scenario.Population expected value of perfect information
analysis (EVPI) in Table 5 showed that the opportunity
cost surrounding the decision to implement any of the
intervention that emerged cost-effective at a given
willingness-to-pay threshold ranged from approximately
$26,000,000 to $73,000,000. This range also implies the
maximum that the providers will be willing to pay in
order to obtain perfect information so as to obtain a per-
fect result. In Table 5, the interventions shown were the
interventions which at a particular willingness-to-pay,
becomes the most cost effective. For any of the risk
states, interventions which are not cost-effective at any
point are not included in the table. The willingness-to-pay
used in Table 5 is the point from which an intervention
emerges as the most cost-effective for a particular risk
state.
Analysis for the expected value of perfect information
for parameters (EVPPI) in Table 6 showed that the
population EVPPI for the various parameters was far
below the population EVPI, indicating that the providers
can easily pay-off such amount to obtain perfect infor-
mation of the parameters. Parameters such as cost of
managing stroke patients and yearly cost of using thia-
zide diuretic has negligible EVPPI for low risk and high
risk state.
Discussion
From the result, thiazide diuretic among the four alter-
natives was the most cost-effective. This finding was
consistent for the 3 cardiovascular risk scenarios. For
low risk patients, lisinopril was the second most cost-
effective option to implement but additional fund needs
to be committed in order to achieve better health out-
comes over thiazide diuretic. CCB was the second most
cost-effective option for medium and high risk patients
if additional fund is committed in order to achieve better
health outcomes over thiazide diuretic. In the graphs,
the probability that thiazide diuretic is cost-effective
decreases as the CE threshold increases. This is so be-
cause beyond a willingness-to-pay of about $2,600/
QALY, committing more funds does not yield a corre-
sponding increase in QALY for thiazide. So, additional
fund beyond $15,000/QALY is a waste of resource since
there is no increase in clinical outcome. Beyond that
limit, CCB should be considered.
From the report of a recent Meta analysis aimed to
quantify the benefits and harm of the major first-line
anti-hypertensive drug classes, thiazide diuretic was the
best choice for hypertension [5]. Most of the evidence
demonstrated that first-line low dose thiazide diuretic
reduces mortality and morbidity (stroke, heart attack
and heart failure). No other drug improved health out-
comes better than low-dose thiazide [5]. This analysis
shows that with cost consideration, low dose thiazide
Table 6 Expected Value of Perfect Information for
Parameters
Parameter Population EVPPI ($) Population EVPI ($)
Low Risk 27,076,912












Yearly Cost Thiazide 178
Moderate Risk 73,353,965












Yearly Cost Thiazide 4,126,641
High Risk 26,667,500












Yearly Cost Thiazide 437,657
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tings such as in Nigeria and other developing countries,
thiazide diuretic should be considered the drug of first
choice especially in patients that respond well to it and
those that do not have other co-morbidities that will ne-
cessitate the use of a particular antihypertensive agent.
That an intervention is most cost-effective depends on
what the providers are willing to pay per outcome. As a
guide, WHO considers interventions to be cost-effective if
they have incremental cost-effectiveness ratios (ICERs)
that are less than three times the gross national income
(GNI) per capita [19]. It is pertinent to state that at 50%
probability of cost-effectiveness, the willingness-to-pay is
less than three times the GNI per capita. The national in-
come per capita for Nigeria in 2009 was USD1, 190 or
USD3, 370 when multiplied by three. Based on the above
premise, thiazide diuretic could be judged a cost-effective
option.
From the University of Toronto, in a published cost-
effectiveness analysis of routine echocardiography in
patients starting antihypertensive drug therapy, the result
of the model showed that ACE-inhibitors cannot be
recommended as antihypertensive first-line therapy in the
patients under study [20]. This was because ACE-
inhibitors were very expensive and the gain in unadjusted
and quality-adjusted life-years was small and clinically
irrelevant [20]. From the author’s result, prescribing con-
ventional antihypertensive therapies (diuretics and beta-
blockers) to everybody can be recommended as strategies
of choice [20]. This is in line with the result of this study
because the result showed that ACE-inhibitors are very
expensive with low QALYs and their ICERs are far more
than three times the GNI of Nigeria.
However, the result of this study does not completely sup-
port the guideline by the Sixth Report of the Joint National
committee on prevention, detection, evaluation and treat-
ment of high blood pressure (JNC- 6) which recommends
the use of diuretics and beta-blockers as first-line antihyper-
tensive drugs in the absence of compelling reasons to use
other antihypertensive drugs [21]. The result of this study
does not also completely support the result in the cost-
effectiveness study from the University of Toronto which
recommended the prescribing of diuretics and beta-blockers
to everybody [20]. This is evidently because, in the result
of this study, beta-blocker was never a contender for cost-
effectiveness. For Nigerians, in place of beta-blocker,
calcium-channel-blocker should be considered a second-
line therapy after diuretics.
In the context of research, with respect to this study,
EVPI represent the maximum that providers can will-
ingly pay for additional research, to inform the decision
they make [22]. The EVPI analysis showed that the op-
portunity cost surrounding the choice of thiazide diur-
etic for all the cardiovascular risk state is lower
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for this is because the willingness-to-pay from which
thiazide diuretic becomes most cost-effective is relatively
small. This supports the fact that thiazide could be
judged a cost-effective option compared to the other
antihypertensive drugs. On the other hand, analysis for
the expected value of perfect information for parameters
(EVPPI) showed that there may not be need of further
experimental research to get perfect parameter estimates
since the population EVPPI for the various parameters
was far below the population EVPI. Change in the para-
meters caused an infinitesimal changed in the result
showing that the result is insensitive to the parameters
which invariably means that the result is robust.
This analysis has some limitations which have to be
considered when interpreting the results. In our Markov
model to show a typical timeline of events consequent
on hypertension, we made use of an algorithm designed
from data obtained from Africans in Britain, which may
not hold true for indigenous Africans and Nigerians in
particular. The reason for use of those data in the model
was because there was no published study that predicted
cardiovascular events over time in Africans that could
be used for this model.
In conclusion, the result of this study shows that thia-
zide diuretic followed by calcium-channel blocker espe-
cially for medium and high risk patients is a cost-effective
option in the management of patients with high blood
pressure in Nigeria.
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